MannKind’s Expansion Strategy
The acquisition allows MannKind to establish a cardiometabolic division alongside its existing orphan lung business, providing new revenue drivers and long-term growth potential.
“This acquisition expands our patient-centered brands and underscores our dedication to advancing therapies for cardiometabolic and orphan lung diseases,” said MannKind CEO Michael Castagna. “With multiple product launches and new indications ahead, we are confident in our ability to accelerate double-digit growth over the next decade.”
To back the deal, MannKind has leaned on its financial partnership with Blackstone, recently securing an additional $175 million through an amended financing agreement. This builds on an August announcement of up to $500 million in non-dilutive capital to support MannKind’s growth initiatives.
Closing Timeline and Legal Teams
The transaction is expected to close in the fourth quarter of 2025, pending regulatory approval and customary closing conditions.
